---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-002528"
form_type: "8-K"
ticker: "TARS"
cik: "0001819790"
company_name: "Tarsus Pharmaceuticals, Inc."
filed_at: "2023-01-05T23:59:59+00:00"
generated_at: "2026-06-20T19:46:45.852920+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tarsus extends $25M second tranche draw to March 2024, reduces interest rate on credit facility

## Summary
- Second tranche of $25M under loan agreement: draw period extended to March 15, 2024; minimum $5M drawn by March 15, 2023 and another $5M by Sept 15, 2023.
- Third tranche of $35M available upon FDA approval of TP-03 for Demodex blepharitis; must be drawn by March 15, 2024.
- First tranche balance of $20M expired undrawn on December 15, 2022.
- Interest rate reduced to prime plus 4.45% (cap 11.45%) or floor 8.45%; no lender fees incurred.
- Regulatory milestone for second tranche draw already achieved.

## SEC filing metadata
- accession: 0001193125-23-002528
- form_type: 8-K
- ticker: TARS
- cik: 0001819790
- company_name: Tarsus Pharmaceuticals, Inc.
- filed_at: 2023-01-05T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819790/000119312523002528/0001193125-23-002528-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819790/000119312523002528/d427625d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-002528
- JSON: https://secwatch.observer/filing/0001193125-23-002528.json
- Plain text: https://secwatch.observer/filing/0001193125-23-002528.txt

## Key facts
- Material Agreements
  Tarsus Pharmaceuticals, Inc. amended First Amendment to Loan and Security Agreement with Hercules Capital, Inc. and Silicon Valley Bank (effective 2023-01-05).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: Hercules Capital, Inc. and Silicon Valley Bank
  - Effective: 2023-01-05
  source text: On January 5, 2023, Tarsus Pharmaceuticals, Inc. (the “Company”), Hercules Capital, Inc. (“Hercules”) and Silicon Valley Bank (“SVB” and together with Hercules, the “Lenders”) entered into a First Amendment to Loan and Security Agreement (the “First Amendment”) to amend that certain Loan and Security Agreement, by and between the Company and the Lenders, dated as of February 2, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819790/000119312523002528/0001193125-23-002528-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.